Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLED1 (Proteoglycan 3, pro-eosinophil major basic protein 2 pseudogene) is classified as a pseudogene located on human chromosome 4q35.1 and is not known to encode a functional protein product[1][5][6]. It is sometimes referred to as RTFV9368 or "proteoglycan 3 pseudogene." Because it is a pseudogene—designated as such due to the presence of mutations or features preventing functional protein expression—it is not considered a therapeutic target, receptor, enzyme, transporter, or any functional molecule with biological, pathological, or pharmacological significance[1][5][6]. There are no known biological functions, disease associations, mechanisms, biomarkers, safety concerns, or drug interactions relevant to this locus. The entry might appear as a candidate in gene lists due to nomenclature overlap with functional proteoglycan family members, but in this case, there is no evidence of physiological or therapeutic relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteoglycan 3, pro-eosinophil major basic protein 2 pseudogene (SLED1).